VK-1727

• Description:

  VK-1727 is a selective small molecule inhibitor of EBNA1. VK-1727 can reduce EBNA1 DNA binding activity. VK-1727 selectively blocks the proliferation and metabolic activity of EBV+ cells, instead of EBV- cells. VK-1727 is used in multiple sclerosis research[1].

• UNSPSC:

  12352005

• Target:

  EBV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/vk-1727.html

• Purity:

  99.88

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C (OC) C1=CC=CC (C#CC2=CC=C (OC3CCOCC3) C=C2) =C1C4=CC5=C (C=C4) C=CN5

• Molecular Formula:

  C29H25NO4

• Molecular Weight:

  451.51

• References & Citations:

  [1]Monaco MCG, et al. EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls. Neurol Neuroimmunol Neuroinflamm. 2023 Aug 10;10 (5) :e200149.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported